An autologous ex vivo model for exploring patient-specific responses to viro-immunotherapy in glioblastoma

Stavrakaki, Eftychia; van den Bossche, Wouter B.L.; Vogelezang, Lisette B.; Teodosio, Cristina; Mustafa, Dana M.; van Dongen, Jacques J.M.; Dirven, Clemens M.F.; Balvers, Rutger K.; Lamfers, Martine L.

doi:10.1016/j.crmeth.2024.100716

Cited by 2 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More advanced ex vivo models, incorporating the tumor microenvironment and/or immune components, such as autologous tumor/PBMC co-cultures, may aid in acquiring further insight into the relationship between OV-induced oncolysis and degree of immune stimulation. 81 Furthermore, concurrently screening of patient-derived tumor samples alongside clinical investigations may assist in the further validation and refinement of the identified molecular signatures.…”

Section: Discussionmentioning

confidence: 99%

The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles

Vazaios,

Stavrakaki,

Vogelezang

et al. 2024

Molecular Therapy: Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles

Vazaios,

Stavrakaki,

Vogelezang

et al. 2024

Molecular Therapy: Oncology

View full text Add to dashboard Cite

“…These models vary in complexity from simple mono-culture spheres to complex organoids, with their common trait being the maintenance of the phenotype and characteristics of the tumour of origin [101,102]. The use of those in vitro techniques has enabled the investigation of the oncolytic efficacy of OVs against multiple types of PBTs and enable the investigation of OV interactions with a limited number of immune cell populations [103,104]. However, with the current technology and knowledge, those models remain insufficient at fully recreating all the events that occur during the treatment and cannot accommodate the multiple factors that would, in practice, affect the efficacy of the treatment.…”

Section: Overcoming Limitations and Obstacles Of Ov Therapy 61 Precli...mentioning

confidence: 99%

OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions

Vazaios,

van Berkum,

Calkoen

et al. 2024

IJMS

View full text Add to dashboard Cite

Oncolytic viruses (OVs) are characterised by their preference for infecting and replicating in tumour cells either naturally or after genetic modification, resulting in oncolysis. Furthermore, OVs can elicit both local and systemic anticancer immune responses while specifically infecting and lysing tumour cells. These characteristics render them a promising therapeutic approach for paediatric brain tumours (PBTs). PBTs are frequently marked by a cold tumour immune microenvironment (TIME), which suppresses immunotherapies. Recent preclinical and clinical studies have demonstrated the capability of OVs to induce a proinflammatory immune response, thereby modifying the TIME. In-depth insights into the effect of OVs on different cell types in the TIME may therefore provide a compelling basis for using OVs in combination with other immunotherapy modalities. However, certain limitations persist in our understanding of oncolytic viruses’ ability to regulate the TIME to enhance anti-tumour activity. These limitations primarily stem from the translational limitations of model systems, the difficulties associated with tracking reliable markers of efficacy throughout the course of treatment and the role of pre-existing viral immunity. In this review, we describe the different alterations observed in the TIME in PBTs due to OV treatment, combination therapies of OVs with different immunotherapies and the hurdles limiting the development of effective OV therapies while suggesting future directions based on existing evidence.

show abstract

An autologous ex vivo model for exploring patient-specific responses to viro-immunotherapy in glioblastoma

Cited by 2 publications

References 35 publications

The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles

The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles

OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions

Contact Info

Product

Resources

About